DOCSLIB.ORG

Review of Equine Analgesics and Pain Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Review of Equine Analgesics and Pain Management SURGERY—LAMENESS Review of Equine Analgesics and Pain Management Nora S. Matthews, DVM, Diplomate ACVA; and Gwendolyn L. Carroll, DVM, Diplomate ACVA Many drugs and administration techniques are now available to the veterinarian for the management of equine pain. Balancing the use of drugs that act at different locations or by different mechanisms in the pain pathway improves analgesia, minimizes cost, and lessens side effects. Providing good analgesia improves the patient’s recovery and shortens hospital stays, thus improving outcome. Au- thors’ address: Department of Veterinary Small Animal Clinical Sciences, Texas A&M University, 4474-TAMU, College Station, TX 77843-4474; e-mail: [email protected]. © 2007 AAEP. 1. Introduction action or that act on different receptor types; these Pain is very debilitating in the horse and may be primar- drugs are used to provide good analgesia with lower ily responsible for the result of euthanasia during certain dosages of each drug, which decreases possible side medical conditions (e.g., laminitis). Yet, adequate pain effects. The simplest (yet widely used) combination ␣ management may be expensive, difficult to evaluate, and of an 2-agonist (e.g., xylazine) for sedation, local may require frequent drug administration. Addition- anesthetic block, and an NSAID provides balanced ally, most commonly used analgesics (i.e., non-steroidal or “multimodal” analgesia. anti-inflammatory drugs [NSAIDs]) come with their own A multitude of such combinations may be formu- set of limiting side effects. lated depending on patient need and intended route Positive benefits of analgesia include mainte- of administration. Currently, many drugs may be nance of weight, shorter hospitalizations, and lower administered parenterally (e.g., IV, IM, or SC) as total patient bills.1 The use of analgesics in horses well as orally (PO). Regional local anesthetic grows as the complexity of surgical treatment in- blocks (e.g., intra-articular [IA], epidural, four- creases. Because equine pain management is a point, etc.), transdermal (TD), and transmucosal large topic, this review will focus on pain manage- (TM) are other routes that may be used. Constant- ment during the perioperative period. The drugs rate infusions (CRIs) of IV drugs allow for consistent and techniques used in perioperative pain manage- blood concentration with overall lower doses; thus, ment are also useful in chronic conditions. there are fewer side effects. 3. Methods of Administration 2. The Concept of Balanced Analgesia The usual routes of administration (IV, IM, SC, epi- The concept of balanced (or multimodal) analgesia is dural injections, and PO) are all very useful, but to use a variety of drugs that have different modes of newer analgesics can be administered transder- NOTES 240 2007 ր Vol. 53 ր AAEP PROCEEDINGS SURGERY—LAMENESS mally by patch or topical application. CRIs allow provided by butorphanol has been questioned, it has for the IV administration of lower doses (fewer side become widely used in equine medicine, particularly effects) to maintain consistent plasma concentra- before being scheduled. Nalbuphinel is another ag- tions, which produces analgesia with fewer peaks onist-antagonist opioid (much like butorphanol) that and troughs. Many drugs may be administered by currently has the advantage of not being a scheduled multiple methods depending on the method that is drug. Nalbuphine (0.3 mg/kg, IV) has been evalu- most practical for the patient. An analgesic regi- ated with detomidinem (0.01 mg/kg, IV) or men might combine different drugs given by differ- acepromazinen (0.05 mg/kg, IV), and it produced ent routes, which could help to reduce injection pain good sedation with both; however, the analgesic ef- or adverse gastrointestinal side effects and improve fect was not evaluated.2 Analgesia (dental dolo- owner compliance. rimetry model) was evaluated with nalbuphine (0.75 mg/kg, IV) and compared with morphine, butorpha- 4. NSAIDs nol, and xylazine.o3 No difference between groups Several different NSAIDs (phenylbutazone,a flunix- was seen. Nalbuphine is less potent and efficacious in,b and ketoprofenc) have been widely and effec- than butorphanol, but it has been used for analge- tively used for pain management in sia, especially in countries where other opioids are horses. However, all have the potential to produce not available. significant side effects, especially when used at high Buprenorphinep (0.004–0.006 mg/kg, IV, IM, or doses. Although not approved for use in horses in SC) has the advantage of a long duration of action the United States, the newer NSAIDs like meloxi- (6–8 h), but it is not approved for equine use (or any camd (0.6 mg/kg, IV) and carprofene (0.7 mg/kg, IV) veterinary use). Buprenorphine (q 8 h) has been may have fewer side effects with good efficacy. used in the multimodal analgesic management of Transdermal 1% diclofenacf may have the advan- laminitis. The TM or PO absorption of buprenor- tage of decreased side effects, because it can be used phine has not been reported in horses. In cats, TM on the specific site where analgesia is required. buprenorphine is 100% bioavailable. A transder- Because all are fairly similar, the choice of NSAID is mal form of buprenorphine is available in the United likely to depend on availability and cost. Indi- Kingdomq and Australia.r vidual patients may vary in their response to a par- Fentanyls is a short-acting, ␮-receptor opioid that ticular NSAID (much as occurs in humans), and this produces increased locomotor activity in horses, an may also affect the choice of drug to use for a par- effect that is similar to the earlier opioid studies that ticular patient. Although NSAIDs are very effec- were reported by Tobin et al.4,5 Transdermal fen- tive for pain reduction in horses, it is unlikely that tanylt (fentanyl patches are now generic) is not ap- they will produce sufficient analgesia for severely proved for use in horses but has been used for painful conditions; however, it should be a basic analgesia. Uptake of transdermal fentanyl is more “building block” of balanced analgesia. The veteri- rapid in the horse; blood levels consistent with an- narian must also remember that severe or chronic algesia are present within4hofapplication com- pain is very difficult to treat; it may be “refractory” pared with 12 h in humans and small animals.6 to analgesics that normally are quite effective. Two 100-mcg/h patches for a 450-kg horse are the Chronic pain requires aggressive and multimodal typical dose. The two patches may be applied to a analgesia for successful treatment. Reasonable clipped area of the skin and bandaged in place to outcome expectations for analgesia may need to in- insure good skin contact. Because it is easy to clude feed consumption and mobility rather than a place a bandage on the forearm or gaskin, these complete return to normal weight bearing. locations are easy sites to use. Although patches are supposed to provide analge- 5. Opioid Analgesics sia for 72 h in people, reapplication at 48 h should be Opioids have been a mainstay of pain relief in both considered depending on response and reevaluation the human and veterinary field. The usefulness of of pain. Systemic fentanyl (1–4 mcg/kg/h) has been opioids as single-agent analgesics in horses has been used in conjunction with inhalant anesthesia to re- tempered by the propensity for opioids to produce duce the vaporizer setting required. However, excitement when administered alone in non-painful when alfentanylu was used with halothane, no min- horses. Gastrointestinal stasis may also occur in imum alveolar concentration (MAC)-sparing effect some horses. Morphineg (0.1 mg/kg, IV or IM), me- was seen in horses, so further research is needed to peridineh (4.4 mg/kg, IV or IM), methadonei (0.22 determine if these drugs are beneficial when used mg/kg, IV), and oxymorphonej (0.033 mg/kg, IV) with inhalant anesthesia.7 Fentanyl is also a po- have all been used alone for analgesia and with tent respiratory depressant, and mechanical venti- sedatives to facilitate standing surgery. lation is required when it is used with inhalant Butorphanolk (schedule IV; 0.01–0.1 mg/kg, IV or anesthesia. IM), an agonist-antagonist opioid approved for use Tramadol,v a non-opiate ␮-agonist for the treat- in the horse in the United States, has also been ment of mild to moderate pain, has the advantage widely used for analgesia and sedation in conjuction that it is not currently a scheduled drug. In addi- ␣ with 2-agonists. Although the degree of analgesia tion to other drug activity, tramadol has analgesic AAEP PROCEEDINGS ր Vol. 53 ր 2007 241 SURGERY—LAMENESS activity similar to ␮-agonists; morphine is the gold used in a variety of ways: local infiltration, ana- standard for ␮-opioid activity). Tramadol is also a tomic nerve block, regional limb block or perfusion, serotonin-reuptake inhibitor, and it lowers the sei- epidural, and CRI. Although lidocainey and mepiv- zure threshold in people. Tramadol is not approved icainez produce a short duration of action, bupivic- for veterinary use, but it is used extensively to treat aineaa offers the advantage of lasting for 6–8 h. mild to moderate pain in dogs and cats. Although Although more toxic (dose should be limited to 2 the efficacy of tramadol has not been documented in mg/kg), bupivicaine may be used as a regional block horses, the pharmacokinetics of oral (10 mg/kg) and (e.g., pastern arthrodesis) intra-operatively and will IV (4 mg/kg) dosing have been reported in foals.8 last into the post-operative period. Local anes- Further investigation is needed for this promising thetic blocks (e.g., blocking the testicle during a drug, especially because the cost has decreased since castration or “splash blocking” ovarian pedicle dur- it became available in generic form.
Load more

Recommended publications
  • 2.0 Synopsis
    Hydrocodone/Acetaminophen Extended Release Tablets M12-807 Abbreviated Clinical Study Report R&D/11/661 2.0 Synopsis Abbott Laboratories Individual Study Table Referring (For National Authority to Part of Dossier: Use Only) Name of Study Drug: Volume: Hydrocodone/Acetaminophen Extended Release Page: Name of Active Ingredient: Hydrocodone 10 mg/ Acetaminophen 650 mg Extended Release Title of Study: A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of Hydrocodone/Acetaminophen Extended Release Compared to Placebo in Subjects with Chronic Low Back Pain Coordinating Investigator: Study Sites: Seventeen investigative sites in the United States Publications: None Studied Period (Years): Phase of Development: 2 First Subject First Visit: 22 June 2011 Last Subject Last Visit: 28 October 2011 Objectives: The primary objective of this study was to compare the analgesic efficacy and safety of 1 tablet of hydrocodone/acetaminophen extended release 10 mg/650 mg administered twice daily over 2 weeks to placebo in subjects with moderate to moderately severe chronic low back pain (CLBP). A secondary objective of this study was to explore the population pharmacokinetics of hydrocodone and acetaminophen resulting from administration of hydrocodone/acetaminophen extended release 10 mg/650 mg tablets. Methodology: This Phase 2, multicenter, double-blind (DB), placebo-controlled, randomized withdrawal study compared the analgesic efficacy and safety of 1 tablet hydrocodone/acetaminophen extended release 10 mg/650 mg to placebo in subjects with moderate to moderately severe CLBP. Subjects met pre-defined criteria at the conclusion of the Open-Label (OL) Titration Period to proceed to randomization into the DB Maintenance Period of the study.
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Basic Function of the Anesthetic Machine, Part II Some Vaporizers Are Filled with Liquid Agent by Using a Pin Fill Device
    Vetamac Vapors (800)334-1583 www.vetamac.com Vol I, Issue 2 Welcome to the second quarterly edition of "Vetamac Vapors". The purpose of this newsletter is to educate your staff with a goal of the best possible patient care. We also would like to inform you of services and products that Vetamac has to offer and to provide support for all of your anesthesia needs. Future editions will cover topics on machines as well as different techniques. Please send comments to the e-mail link at www.vetamac.com. Basic Function of the Anesthetic Machine, Part II Some vaporizers are filled with liquid agent by using a pin fill device. There is an agent specific spout that replaces the cap on the The anesthetic machine must deliver vaporized anesthetic agent bottle. There is a keyed pin that fits into the fill manifold on the agent to the breathing circuit in concentrations that are optimal for the vaporizer. It is locked into place and the vaporizer is filled to the de- sired level on the window. Most vaporizers used in the U.S. have a desired effect. Since the liquid agent is in a closed system, a carrier funnel fill device and the liquid agent is simply poured into the vapor- gas must be present to deliver the vaporized agent to the breathing izer. Care must be exercised to avoid spillage. Anti-Spil™ adapters circuit. The gas used to accomplish this is the fresh gas flow of oxy- are available that replace the cap on the agent bottle and minimize the gen.
    [Show full text]
  • Nubain Product Monograph.Pdf
    PRODUCT MONOGRAPH ©NUBAIN (Nalbuphine Hydrochloride) Injection, 10 mg/mL Opioid Analgesic Adjunct Anesthetic Sandoz Canada Inc. 145 Jules-Léger Boucherville, Quebec, J4B 7K8 Date of Revision: April 03, 2018 Submission Control No: 213120 Nubain Page 1 of 34 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ............................................. 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................... 3 CONTRAINDICATIONS .............................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................. 4 ADVERSE REACTIONS ............................................................................................. 12 DRUG INTERACTIONS ............................................................................................. 14 DOSAGE AND ADMINISTRATION ......................................................................... 15 OVERDOSAGE ........................................................................................................... 18 ACTION AND CLINICAL PHARMACOLOGY ....................................................... 19 STORAGE AND STABILITY ..................................................................................... 20 SPECIAL HANDLING INSTRUCTIONS .................................................................. 20 DOSAGE FORMS, COMPOSITION
    [Show full text]
  • The Parenteral Opioid Shortage: Causes and Solutions Hanna Hollingsworth, Pharmd; Chris Herndon, Pharmd, CPE
    JOM_Hollingsworth_Editorial 4/25/2018 9:33 AM Page 81 DOI:10.5055/jom.2018.0434 EDITORIal The parenteral opioid shortage: Causes and solutions Hanna Hollingsworth, PharmD; Chris Herndon, PharmD, CPE Key words: Opioids, shortage, protocol, ketamine, the quotas are created, which prevents accumula - nalbuphine, butorphanol tion of reserve stock and ultimately puts them at risk Growing scarcity of several parenteral opioids for experiencing a shortage. 3 threatens to compromise patient care by either delay - Often though, the source of drug shortages origi - ing or preventing their use in the treatment of acute nates from drug manufacturers. Considering that a sub - pain. This shortage is a serious dilemma in healthcare, stantial amount of drug shortages affects sterile with health systems across the United States struggling injectable products, it is reasonable to question the role to maintain dwindling supplies of morphine, hydro - of quality control failure. In 2011, 56 percent of report - morphone, and fentanyl. In addition to creating barri - ed reasons for sterile injectable drug shortages were ers to timely and effective treatment, patient safety due to quality, but this percentage may be an underes - also becomes a potential concern. Reliance on higher timate. 4 Although Pfizer does not state in their “Dear concentration formulations of these high-alert medica - Customer” letter that the upgrades at their Hospira tions increases the risk for errors leading to overdose. (owned by Pfizer) plant in McPherson, Kansas are a Although oral alternatives exist, parenteral opioids reaction to quality problems, a published warning let - remain essential analgesics for those with swallowing ter from the FDA to Hospira indicates that this is pre - or absorption limitations, post-operative pain, chest cisely why its facility is undergoing upgrades.
    [Show full text]
  • Treating Pregnant Patients with Opioid Use Disorder
    OKLAHOMA OPIOID PRESCRIBING GUIDELINES TREATING PREGNANT PATIENTS WITH OPIOID USE DISORDER Note: These guidelines do not replace clinical judgment in the appropriate care of patients. They are not intended as standards of care or as templates for legislation, nor are they meant for patients in palliative care programs or with cancer pain. The recommendations are an educational tool based on the expert opinion of numerous physicians and other health care providers, medical/nursing boards, and mental and public health officials.1,2,3,4,5 Although the recommendations do not include language on Oklahoma’s opioid-related laws, it is imperative that providers maintain compliance. During pregnancy: 1. All patients should receive early screening for substance use 3. Medically-supervised withdrawal is NOT recommended during disorder. When indicated, patients should receive in-practice pregnancy or shortly after delivery. intervention and be referred to appropriate treatment for a full, individualized assessment to determine the intensity and 4. For patients receiving chronic opioid therapy, maintain pre- duration of care. pregnancy dose or transition to methadone or buprenorphine to treat pain and avoid opioid withdrawal symptoms. 2. Medication-assisted treatment (MAT) is the recommended standard of care for women with opioid use disorder. Either 5. In patients who require additional pain medication during methadone or buprenorphine may be used. Referral should pregnancy for an acute event, opioid prescribing by the be made to an MAT provider for initiation in pregnant patients obstetric care provider should be carefully coordinated with who have the diagnosis of opioid use disorder and desire to the MAT provider and be for the shortest duration possible.
    [Show full text]
  • Total Solutions for Anesthesia & Surgery
    total solutions for Anesthesia & Surgery Ventilation Anesthesia Animal Surgery Temperature Control Physiological Monitoring NEW Catalogs Other Catalogs from Harvard Apparatus 2010 BTX Electroporation Catalog BTX offers a comprehensive line of instruments and accessories for both electroporation and electrofusion of mammalian, bacterial, yeast, fungi, insect and plant cells and tissues. BTX specializes in providing research tools for novel cutting edge applications such as adherent cell electroporation, high- throughput cloning, in vivo gene delivery, in ovo gene delivery, and in & ex utero gene delivery. 2009 Warner 2010 Animal, Organ & Cell Physiology Electrophysiology and This catalog features a broad range of products, including our Cell Biology Catalog legendary line of infusion and perfusion pumps, ventilators and anesthesia systems, surgical instruments and equipment for small For the electrophysiological, cellular, and to larger animals, and isolated organ and tissue systems for all neurological sciences. Our extensive levels of research and education. These products are designed to product line includes voltage and current help you achieve better research results in less time. clamp amplifiers for whole-cell and patch applications. Bessel filters, chambers for imaging and recording systems, perfusion control systems and steppers, 2010 Molecular solution heating systems, microscope translation tables, microelectrodes and holders, and glass capillary tubing, plus Sample Preparation now includes electroporation and transfection systems
    [Show full text]
  • HEYER Pasithec
    Anesthesia System Operator’s Manual Rev. 0.2 Draft – 12/09 INNOVATION IN DESIGN AND TECHNOLOGY HEYER Pasithec Contents 1 Statement .......................................................................................................................................................................... 5 1.1 Manufacturer Responsibility...................................................................................................................................... 5 1.2 Security, Reliability and Operating Conditions........................................................................................................... 5 1.3 Return ...................................................................................................................................................................... 6 1.4 Details of the Manufacturer....................................................................................................................................... 6 2 Introduction........................................................................................................................................................................ 7 2.1 Intended Use............................................................................................................................................................ 7 2.1.1 Range of Use .................................................................................................................................................. 7 2.1.2 Contraindication .............................................................................................................................................
    [Show full text]
  • CORRESPONDENCE Does Restrictive
    Ⅵ CORRESPONDENCE Anesthesiology 2006; 104:889 © 2006 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Does Restrictive Intraoperative Fluid Management Alter Outcome after Intraabdominal Surgery? To the Editor:—I read with great interest the recent article by Nisanev- confidence interval includes 1 and so would not be taken to indicate a ich et al.1 suggesting that restricted fluid therapy for intraabdominal statistical difference between the two therapies. surgery reduces postoperative morbidity. My comments focus on the The authors mention the use of the Newman-Keuls adjustment, but description of the statistical methods and their application to the data. that correction only applies if the group means are independent, The authors mention the use of both the chi-square test and Fisher which is clearly not the case here. Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/104/4/890/361043/0000542-200604000-00040.pdf by guest on 02 October 2021 exact test for the analysis of categorical data. However, it seems that No advanced statistical methods are used to model the data and only the results for the chi-square test are reported: For the number of explain the impact of relevant covariates. In particular, logistic regres- patients with complications, the Fisher exact test gives a nonsignificant sion could be used to model the presence of a complication on the P value of 0.056. The authors should explain why they report the number of fluid boluses, the degree of hypotension, the duration of results of one test and not the other. surgery, or American Society of Anesthesiologists physical status.
    [Show full text]
  • Citation Classics and Trends in the Field of Opioids: a Bibliometric Analysis
    Open Access Original Article DOI: 10.7759/cureus.5055 Citation Classics and Trends in the Field of Opioids: A Bibliometric Analysis Hira F. Akbar 1 , Khadijah Siddiq 2 , Salman Nusrat 3 1. Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, PAK 2. Internal Medicine, Civil Hospital Karachi, Dow University of Health Sciences, Karachi, PAK 3. Gasteroenterology, University of Oklahoma Health Sciences Center, Oklahoma City, USA Corresponding author: Hira F. Akbar, [email protected] Abstract Introduction Bibliometric analysis is one of the emerging and latest statistical study type used to examine and keep a systemic record of the research done on a particular topic of a certain field. A number of such bibliometric studies are conducted on various topics of the medical science but none existed on the vast topic of pharmacology - opioids. Hence, we present a bibliometric analysis of the ‘Citation Classics’ of opioids. Method The primary database chosen to extract the citation classics of opioids was Scopus. Top 100 citation classics were arranged according to the citation count and then analyzed. Results The top 100 citation classics were published between 1957 and 2013, among which seventy-two were published from 1977 to 1997. Among all nineteen countries that contributed to these citation classics, United States of America alone produced sixty-three classics. The top three journals of the list were multidisciplinary and contained 36 citation classics. Endogenous opioids were the most studied (n=35) class of opioids among the citation classes and the most studied subject was of the neurosciences. Conclusion The subject areas of neurology and analgesic aspects of opioids are well established and endogenous and synthetic opioids were the most studied classes of opioids.
    [Show full text]